The SLC22A18 Polyclonal Antibody (PACO12254) is a valuable tool for researchers studying SLC22A18, a member of the solute carrier family involved in transporting organic cations. This antibody, produced in rabbits, exhibits high reactivity with human samples and is suitable for use in Western blotting applications. By targeting the SLC22A18 protein, this antibody enables accurate detection and analysis in various cell types, making it an ideal choice for investigations in the fields of pharmacology and oncology.SLC22A18 plays a crucial role in the transport and metabolism of endogenous and exogenous substances, making it a key player in drug absorption and distribution.
As such, understanding the function and regulation of SLC22A18 is essential for developing therapies targeting drug transport mechanisms and optimizing drug delivery in clinical settings. This antibody provides researchers with a powerful tool to further explore the role of SLC22A18 in various physiological processes and pathological conditions, paving the way for potential therapeutic advancements.
solute carrier family 22, member 18;SLC22A18;BWR1A;BWSCR1A;DKFZp667A184;HET;IMPT1;ITM;ORCTL2;SLC22A1L;TSSC5;p45-BWR1A ;
UniProt Protein Function:
SLC22A18: May act as a transporter of organic cations based on a proton efflux antiport mechanism. May play a role in the transport of chloroquine and quinidine-related compounds in kidney. Defects in SLC22A18 are associated with lung cancer (LNCR). LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Defects in SLC22A18 are a cause of rhabdomyosarcoma type 1 (RMS1). It is a form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchimal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas. Belongs to the major facilitator (TC 2.A.1) superfamily. Organic cation transporter (TC 2.A.1.19) family.Protein type: Membrane protein, multi-pass; Transporter; Transporter, SLC family; Membrane protein, integralChromosomal Location of Human Ortholog: 11p15.5Cellular Component: membrane; cytoplasm; apical plasma membrane; plasma membrane; integral to membrane; nuclear envelopeMolecular Function: symporter activity; ubiquitin protein ligase binding; drug transporter activityBiological Process: organic cation transport; drug transport; multidrug transport; excretion; transmembrane transportDisease: Lung Cancer; Breast Cancer; Rhabdomyosarcoma, Embryonal, 1
UniProt Protein Details:
NCBI Summary:
This gene is one of several tumor-suppressing subtransferable fragments located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. This gene is imprinted, with preferential expression from the maternal allele. Mutations in this gene have been found in Wilms' tumor and lung cancer. This protein may act as a transporter of organic cations, and have a role in the transport of chloroquine and quinidine-related compounds in kidney. Two alternatively spliced transcript variants encoding the same protein have been described. [provided by RefSeq, Oct 2010]